Most kidney transplant candidates are on the waiting list at a transplant center in their local area. In most cases, transplant centers use the local OPO or, if there is more than one OPO in an area, transplant centers may choose the OPO to list their transplant patients. According to a ...
Transplant. Rev. 1997; 11: 70–75.Ozminkowski RJ, Hassol A, White A, Murphy M, Dennis JM, Shield CF. Socioeconomic factors and multiple listing for cadav- eric kidney transplantation among Medicare End Stage Renal Dis- ease Program beneficiaries. Transplant Rev 1997; 11: 70-75....
We evaluated the association between multilisting (ML) status and access to a deceased donor kidney transplant (DDKT) to determine if ML provides a long-term advantage regarding wait-list mortality and recipient outcomes. Materials and Methods Candidates between January 2010 and October 2017 were ...
Methods We reviewed the records of 225 adult kidney transplants done consecutively at our institution. Twenty-nine patients (12.8%) had grafts with multiple renal arteries. We analyzed the incidence of post-transplant hypertension and vascular complications, mean creatinine levels, patient and graft ...
The risk of bladder, brain, cervical, and kidney cancer was significantly increased in MS… October 3, 2024 News by Steve Bryson, PhD Sublingual cladribine shown equivalent to MS treatment Mavenclad A sublingual formulation of cladribine, which is the active ingredient of the approved oral ...
Autologous peripheral stem cell transplantation for multiple myeloma in a patient with a 10 year-old kidney transplant: case report and clinical issues 喜欢 0 阅读量: 29 作者:F Rego,P Alcantara,F Buinho,F Araujo,JM Costa Santos,A Parreira,dCF Leal ...
www.nature.com/scientificreports OPEN received: 25 February 2016 accepted: 19 August 2016 Published: 16 September 2016 A diverse virome in kidney transplant patients contains multiple viral subtypes with distinct polymorphisms Asha Rani1,*, Ravi Ranjan1,*, Halvor S. McGee1, Ahmed ...
mediating the interaction between T cells and HER2+ tumor cells, thereby activating cytotoxic T cells to target HER2-expressing cancer cells effectively. Mice treated with aCD3-aHER2 SMART-Exos displayed remarkable suppression of tumor growth without any observed liver or kidney damage. Furthermore, ...
EP: 2.Eligibility Factors in Multiple Myeloma Transplant EP: 3.Multiple Myeloma Care: Pharmacist Team Collaboration EP: 4.Multiple Myeloma Regimen Comparisons EP: 5.Pharmacist's Role in Enhancing Multiple Myeloma Care EP: 6.Choosing Multiple Myeloma Regimens EP: 7.Pharmacists' Patient Counseling Role...
Experts discuss the impact of advances in the treatment of multiple myeloma on patient care. This video discusses the evolving landscape of bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM). The specialists are Ryan Haumschild, PharmD, MS, MBA; hematologist Matthew Pianko, ...